These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35674938)

  • 21. Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis.
    Alegre-Sancho JJ; Núñez-Monje V; Campos-Fernández C; Balaguer-Trull I; Robustillo-Villarino M; Aguilar-Zamora M; Garijo-Bufort M; Pedraz-Penalva T; Peña-González C; de la Morena I; Bedoya-Sanchís D; Yankova-Komsalova L; Conesa-Mateos A; Martinez-Cristóbal A; Navarro-Blasco FJ; Senabre-Gallego JM; Sivera F
    Front Med (Lausanne); 2023; 10():1294247. PubMed ID: 38053615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients.
    Moskal M; Krawiec P; Zaręba W; Świerczek I; Ratusznik J; Raputa W; Zieliński M; Batko K; Huk M; Batko B
    Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36497938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
    Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
    Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis.
    Ogdie A; Gladman DD; Coates LC; Pournara E; Parikh B; Mease PJ
    Rheumatol Ther; 2023 Aug; 10(4):849-860. PubMed ID: 37148474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Blachley T; Dube B; McLean RR; Kim N; Hur P; Ogdie A
    J Rheumatol; 2022 Jul; 49(7):700-706. PubMed ID: 35428716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations.
    Baraliakos X; Pournara E; Coates LC; Mease PJ; Jahandideh SS; Gladman DD
    Clin Exp Rheumatol; 2024 Mar; 42(3):696-701. PubMed ID: 38019168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis - a real life retrospective study.
    Galica K; Lesiak A; Ciążyńska M; Noweta M; Bednarski I; Narbutt J
    Postepy Dermatol Alergol; 2021 Dec; 38(6):973-978. PubMed ID: 35126003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
    Gottlieb AB; Deodhar A; Mcinnes IB; Baraliakos X; Reich K; Schreiber S; Bao W; Marfo K; Richards HB; Pricop L; Shete A; Trivedi V; Keefe D; Papavassilis CC; Jagiello P; Papanastasiou P; Mease PJ; Lebwohl M
    Acta Derm Venereol; 2022 Apr; 102():adv00698. PubMed ID: 35146532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting.
    Al-Homood IA; Alajlan M; Alberdisi M; Alturki M; Ahmed AA; Zakaria N
    Adv Rheumatol; 2024 Apr; 64(1):34. PubMed ID: 38685124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
    Baraliakos X; Braun J; Deodhar A; Poddubnyy D; Kivitz A; Tahir H; Van den Bosch F; Delicha EM; Talloczy Z; Fierlinger A
    RMD Open; 2019; 5(2):e001005. PubMed ID: 31565244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real world effectiveness and satisfaction with secukinumab in the treatment of patients with psoriatic arthritis: a population survey in five European countries.
    Conaghan PG; Keininger DL; Holdsworth EA; Booth N; Modi NN; Tian H; Kiltz U
    Curr Med Res Opin; 2021 Oct; 37(10):1845-1853. PubMed ID: 34256669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
    Conesa-Nicolás E; García-Lagunar MH; Núñez-Bracamonte S; García-Simón MS; Mira-Sirvent MC
    Farm Hosp; 2020 Dec; 45(1):16-21. PubMed ID: 33443473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension.
    D'Agostino MA; Carron P; Gaillez C; Conaghan PG; Naredo E; López-Rdz A; Šenolt L; Burgos-Vargas R; Hanova P; Padovano I; Cazenave T; Stoenoiu MS; Backhaus M; Mouterde G; Bao W; Goyanka P; Boers M; Schett G
    Semin Arthritis Rheum; 2023 Dec; 63():152259. PubMed ID: 37660536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Retrospective Study on the Effectiveness of Ixekizumab After Treatment With Secukinumab for Patients With Active Psoriatic Arthritis.
    Darabian S; Badii M; Dutz JP; Chan J
    J Psoriasis Psoriatic Arthritis; 2022 Jan; 7(1):13-16. PubMed ID: 39296732
    [No Abstract]   [Full Text] [Related]  

  • 35. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    BMJ Open; 2018 Jun; 8(6):e021082. PubMed ID: 29903793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secukinumab for ankylosing spondylitis and psoriatic arthritis.
    Lubrano E; Perrotta FM
    Ther Clin Risk Manag; 2016; 12():1587-1592. PubMed ID: 27799780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study.
    McInnes IB; Mease PJ; Kivitz AJ; Nash P; Rahman P; Rech J; Conaghan PG; Kirkham B; Navarra S; Belsare AD; Delicha EM; Pricop L
    Lancet Rheumatol; 2020 Apr; 2(4):e227-e235. PubMed ID: 38268157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study.
    Ortolan A; Lorenzin M; Leo G; Pampaloni F; Messina F; Doria A; Piaserico S; Ramonda R
    Dermatology; 2022; 238(5):897-903. PubMed ID: 35263743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.
    Kivitz AJ; Wagner U; Dokoupilova E; Supronik J; Martin R; Talloczy Z; Richards HB; Porter B
    Rheumatol Ther; 2018 Dec; 5(2):447-462. PubMed ID: 30121827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secukinumab for the treatment of psoriatic arthritis.
    Baronaite Hansen R; Kavanaugh A
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1027-36. PubMed ID: 27550397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.